Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H30F3N3O4 |
| Molecular Weight | 493.5186 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CC1=CC(C(N)=O)=C2N(CCCO)C=CC2=C1)NCCOC3=CC=CC=C3OCC(F)(F)F
InChI
InChIKey=VICSLOHTZDWOFF-QGZVFWFLSA-N
InChI=1S/C25H30F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-7,10,14-15,17,30,32H,4,8-9,11-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
KMD-3241 (Dehydro Silodosin) is a silodosin metabolite (also known as an impurity of Silodosin). Silodosin is a selective antagonsit of alpha-1a adrenergic receptor which was developed by Kissei Pharmaceutical and approved by FDA under the name Rapaflo for the treatment of signs and symptoms associated with benign prostatic hyperplasia. The affnities of silodosin metabolites, KMD-3241, KMD-3289 and
KMD-3295, for alpha1A-AR subtype receptor were equal to or lower than that of silodosin.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9891871
Created by
admin on Mon Mar 31 23:27:06 GMT 2025 , Edited by admin on Mon Mar 31 23:27:06 GMT 2025
|
PRIMARY | |||
|
6787MV7QU0
Created by
admin on Mon Mar 31 23:27:06 GMT 2025 , Edited by admin on Mon Mar 31 23:27:06 GMT 2025
|
PRIMARY | |||
|
DTXSID20432445
Created by
admin on Mon Mar 31 23:27:06 GMT 2025 , Edited by admin on Mon Mar 31 23:27:06 GMT 2025
|
PRIMARY | |||
|
175870-21-0
Created by
admin on Mon Mar 31 23:27:06 GMT 2025 , Edited by admin on Mon Mar 31 23:27:06 GMT 2025
|
PRIMARY |
PARENT (METABOLITE)
SUBSTANCE RECORD
